Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Blood (2023) 142 (Supplement 1): 6907.

https://doi.org/10.1182/blood-2023-181999

Published: 2023

Journal Articles

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

Giulio Cassanello, Efrat Luttwak, Sean M. Devlin, Alejandro Luna De Abia, Magdalena Corona, Ivan Landego, Allison Parascondola, Amethyst Saldia, Ana Alarcon Tomas, Parastoo B. Dahi, Richard J. Lin, M. Lia Palomba, Jae H. Park, Gilles Salles, Miguel-Angel Perales, Michael Scordo, Roni Shouval, Gunjan L. Shah

Blood (2023) 142 (Supplement 1): 6898.

https://doi.org/10.1182/blood-2023-190500

Published: 2023

Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter

Blood (2023) 142 (Supplement 1): 617.

https://doi.org/10.1182/blood-2023-184862

Published: 2023

Journal Articles

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

Blood (2023) 142 (Supplement 1): 7156.

https://doi.org/10.1182/blood-2023-190332

Published: 2023

Journal Articles

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Blood (2023) 142 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2023-181997

Published: 2023

Journal Articles

Higher CD4+ T Cell Counts after CAR-T in Large B-Cell Lymphomas Are Significantly Associated with Better Overall Survival

Danny Luan, Roni Shouval, Teng Fei, Efrat Luttwak, Alejandro Luna, Magdalena Corona, Maria Lia Palomba, Allison Parascondola, Michael Scordo, Gunjan L. Shah, Susan DeWolf, Miguel-Angel Perales

Blood (2023) 142 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2023-184909

Published: 2023

Journal Articles

18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2023-179641

Published: 2023

Journal Articles

Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Blood (2023) 142 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2023-187783

Published: 2023

Journal Articles

Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4889.

https://doi.org/10.1182/blood-2023-187240

Published: 2023

Journal Articles

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6908.

https://doi.org/10.1182/blood-2023-187338

Published: 2023

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

Journal Articles

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, Pilar Giraldo, Blanca Xicoy, Luis Felipe Casado, Fermin Sanchez-Guijo, Concepción Ruiz Nuño, Melania Moreno Vega, Alberto Alvarez-Larran, Araceli Salamanca Cuenca, Ana García-Noblejas, Ferran Vall-Llovera, Manuel Perez Encinas, Lucia Villalon, Natalia De las Heras, Sunil Lakhwani, Elena Ramila, Beatriz Cuevas, Raul Perez Lopez, Antonio Jiménez-Velasco, Ana Rosell, Angeles Escola, Maria Jose Fernández, Carmen Garcia-Hernandez, Carlos Cervero, Elvira Mora Casterá, Miguel Sagüés, Sara Suarez-Varela, Patricia Vélez, Patricia Carrascosa Mastell, Rocio Fé Bitaube, Luis Serrano, Montse Cortes, Juan Antonio Juan Vera Goñi, Juan Luis Steegmann, Juan Carlos Hernandez Boluda, Valle Gomez, Juan Manuel Alonso-Dominguez, Mercedes Colorado Araujo, Antonio Paz Coll, Valentín Garcia Gutierrez

Blood (2021) 138 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2021-150813

Published: 2021

Journal Articles

The Importance of Disease Burden after Induction and Prior to Transplantation in Patients with Acute Myeloid Leukaemia Receiving Allogeneic Transplantation

Claudia Nunez-Torron, Carlos Jimenez Chillon, Fernando Martin Moro, Alejandro Luna, Adolfo Saez, Kyra Velázquez-Kennedy, Juan Marquet Palomanes, Miguel Piris-Villaespesa, Valentín Garcia-Gutiérrez, Anabelle Chinea, Gemma Moreno Jiménez, Javier López Jiménez, Pilar Herrera

Blood (2021) 138 (Supplement 1): 3931.

https://doi.org/10.1182/blood-2021-149494

Published: 2021

Journal Articles

Prognosis Impact of Positive Minimal Residual Disease By Flow Cytometry Prior to Transplant According to the Cut-Off Threshold in Patients with Acute Myeloid Leukemia

Claudia Nunez-Torron, MD, Fernando Martin Moro, Juan Marquet Palomanes, Miguel Piris-Villaespesa, MD, Ernesto Roldan, Alejandro Luna, MD, Adolfo Saez, Valentín Garcia-Gutiérrez, MD PhD, Lucía Rubio, Maria Eulalia Rodriguez, Anabelle Chinea, MD, Ana Lario, Gemma Moreno Jiménez, MD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-139954

Published: 2020

Journal Articles

Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes According to the Different Subgroups of the WHO 2016 Classification in Patients Candidates to Intensive Chemotherapy

Claudia Nunez-Torron, MD, Juan Marquet Palomanes, Valentín Garcia-Gutiérrez, MD PhD, Adolfo Saez, Alejandro Luna, MD, Jesus Villarrubia, PhD, Gemma Moreno Jiménez, MD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141683

Published: 2020

Journal Articles

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-138690

Published: 2020

Journal Articles

Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission

Valentín Garcia-Gutiérrez, MD PhD, Lorena Vigon, Laura Checa, Alejandro Luna, MD, Miguel Piris-Villaespesa, MD, Sara Rodriguez-Mora, Guiomar Bautista, Juan Luis Steegmann, Prof., MD, Vicente Planelles, Jose Alcamí, Maria Rosa López-Huertas, Maria Teresa Coiras

Blood (2019) 134 (Supplement_1): 191.

https://doi.org/10.1182/blood-2019-130017

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

Blood (2019) 134 (Supplement_1): 3325.

https://doi.org/10.1182/blood-2019-126507

Published: 2019

Journal Articles

Survival Analysis According to Minimal Residual Disease By Flow Cytometry in Acute Myeloid Leukemia after First Induction

Claudia Nunez-Torron, MD, Juan Marquet Palomanes, MD, Fernando Martín Moro, Adolfo Saez-Martin, MD, Alejandro Luna, MD, Irene Garcia-Garcia, Berta Mercedes Michael Fernández, Jesus Villarrubia, PhD, Miguel Piris-Villaespesa, MD, Ernesto Roldan Santiago, Eulalia Rodríguez Martín, Gemma Moreno, MD, Valentín García Gutiérrez, PhD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2019) 134 (Supplement_1): 1433.

https://doi.org/10.1182/blood-2019-130190

Published: 2019

NARROW

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Higher CD4+ T Cell Counts after CAR-T in Large B-Cell Lymphomas Are Significantly Associated with Better Overall Survival

18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma

Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

The Importance of Disease Burden after Induction and Prior to Transplantation in Patients with Acute Myeloid Leukaemia Receiving Allogeneic Transplantation

Prognosis Impact of Positive Minimal Residual Disease By Flow Cytometry Prior to Transplant According to the Cut-Off Threshold in Patients with Acute Myeloid Leukemia

Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes According to the Different Subgroups of the WHO 2016 Classification in Patients Candidates to Intensive Chemotherapy

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission

Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

Survival Analysis According to Minimal Residual Disease By Flow Cytometry in Acute Myeloid Leukemia after First Induction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only